Structured symptom rating administration

The manuals converge on the need for structured, standardised symptom rating, with trained administration and interpretation of validated scales used to track baseline status, change over time, and treatment response. Across the extracts, the shared emphasis is on accurate scoring, consistent administration, and using rating scales as part of outcome evaluation rather than relying on unstructured impressions. They also overlap in using clinician-rated measures to capture broader psychiatric state. MADRS and HAM-D appear in the depression-focused manuals, while BPRS is used across both the 5-MeO-DMT and ayahuasca extracts to assess wider symptom domains. The ayahuasca study adds YMRS and CADSS, showing that some manuals extend structured rating beyond depression into mania and dissociation, while the 5-MeO-DMT source also refers to PGI-S and PGI-I for patient-rated severity and improvement. The main difference is that the ADHD trial is more explicit about operational scoring rules and eligibility consequences. It names AISRS, CGI-S, ASRS, and CAARS, and includes a protocol rule that a 13-point AISRS change between screening and baseline excludes randomization. By contrast, the psychedelic depression sources focus more on symptom domains and baseline characterisation, with less detail on threshold-based trial decisions.